Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Nooka

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Haematologica|August 13, 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesDavid Siegel, Thomas Martin, Ajay Nooka, et al.
Transfusion|September 3, 2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trialNeera Jagirdar, R Donald Harvey, Ajay Nooka, et al.
American Journal of Hematology|March 27, 2025
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-AnalysisJoshua Richter, Ajay Nooka, Paula Rodríguez-Otero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myelomaR Donald Harvey, Jonathan L Kaufman, Heather R Johnson, et al.
Blood Cancer Discovery|June 28, 2021
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcareNicole Gormley, Lola Fashoyin-Aje, Trevan Locke, et al.
Oncology|September 21, 2013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinomaAhmed O Kaseb, Mohamed Shama, Ibrahim Halil Sahin, et al.
Southern Medical Journal|August 2, 2014
Incidence and geographic distribution of adult acute leukemia in the state of GeorgiaFuad El Rassi, Kevin C Ward, Christopher R Flowers, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 8, 2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphomaRajni Sinha, Pareen J Shenoy, Nassoma King, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 19, 2008
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesAna O Hoff, Béla B Toth, Kadri Altundag, et al.
British Journal of Haematology|May 28, 2021
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapyHang Quach, Ajay Nooka, Olga Samoylova, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Haematologica|August 13, 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesDavid Siegel, Thomas Martin, Ajay Nooka, et al.
Transfusion|September 3, 2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trialNeera Jagirdar, R Donald Harvey, Ajay Nooka, et al.
American Journal of Hematology|March 27, 2025
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-AnalysisJoshua Richter, Ajay Nooka, Paula Rodríguez-Otero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myelomaR Donald Harvey, Jonathan L Kaufman, Heather R Johnson, et al.
Blood Cancer Discovery|June 28, 2021
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcareNicole Gormley, Lola Fashoyin-Aje, Trevan Locke, et al.
Oncology|September 21, 2013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinomaAhmed O Kaseb, Mohamed Shama, Ibrahim Halil Sahin, et al.
Southern Medical Journal|August 2, 2014
Incidence and geographic distribution of adult acute leukemia in the state of GeorgiaFuad El Rassi, Kevin C Ward, Christopher R Flowers, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 8, 2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphomaRajni Sinha, Pareen J Shenoy, Nassoma King, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 19, 2008
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesAna O Hoff, Béla B Toth, Kadri Altundag, et al.
British Journal of Haematology|May 28, 2021
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapyHang Quach, Ajay Nooka, Olga Samoylova, et al.
Pageof 5